рынок тестирования на месте в южной африке и европе к 2030 году.

South Africa And Europe Poct Market

Размер рынка в млрд долларов США

CAGR : 9.30 %

Прогнозируемый период	2023 –2030
Размер рынка (базовый год)	USD 8,565.13 Million
Размер рынка (прогнозируемый год)	USD 17,289.45 Million
CAGR	9.30 %
Основные игроки рынка	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Запрос на разблокировку

Рынок тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе по типу продукта (продукты для мониторинга уровня глюкозы, продукты для тестирования на инфекционные заболевания, продукты для кардиометаболического мониторинга, продукты для тестирования на беременность и фертильность, продукты для гематологического тестирования, продукты для мониторинга коагуляции, продукты для тестирования на наркотики, вызывающие зависимость (DOA), продукты для анализа мочи, продукты для тестирования холестерина, продукты для тестирования на маркеры опухолей/рака, продукты для тестирования кала на скрытую кровь и другие), применение (глюкоза в крови, кардиомониторинг, гематологическое свертывание, анализ цельной крови, мониторинг основных показателей жизнедеятельности, неинвазивный мониторинг Spo2, неинвазивный мониторинг Pco2, переливание крови и другие), режим рецепта (тестирование по рецепту и без рецепта), платформа (анализы бокового потока/иммунохроматографические тесты, тест-полоски, молекулярная диагностика , иммуноанализы, Микрофлюидика , клиническая химия, гематология и другие), конечный пользователь (клиники, уход на дому, больницы, лаборатории, центры амбулаторной хирургии и другие), канал сбыта (прямые тендеры, розничные продажи, онлайн-продажи и другие) — тенденции отрасли и прогноз до 2030 года.

Анализ и идеи рынка тестирования в пунктах оказания медицинской помощи (POCT) в Южной Африке и Европе

Одним из основных факторов, способствующих росту рынка тестирования в точках оказания медицинской помощи (POCT) в Южной Африке и Европе, является растущая распространенность различных хронических и инфекционных заболеваний. Растущая осведомленность о продуктах для тестирования в точках оказания медицинской помощи приводит к расширению рынка. На рынок также влияет интенсивная конкуренция среди участников рынка. Однако высокая стоимость, связанная с продуктами POCT, может стать сдерживающим фактором для рынка в прогнозируемый период.

С другой стороны, растущая осведомленность и государственное финансирование выступают в качестве возможностей для роста рынка. Однако отсутствие согласованности с результатами тестов, полученными из лабораторий, может создать проблемы для рынка тестирования в точках оказания медицинской помощи (POCT) в Южной Африке и Европе.

Ожидается, что рынок тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе будет расти в прогнозируемый период с 2023 по 2030 год. По данным Data Bridge Market Research, среднегодовой темп роста рынка составит 9,3% в прогнозируемый период с 2023 по 2030 год, и ожидается, что к 2030 году объем рынка достигнет 17 289,45 млн долларов США по сравнению с 8 565,13 млн долларов США в 2022 году.

Отчет Метрика	Подробности
Прогнозируемый период	2023-2030
Базовый год	2022
Исторические годы	2021 Настраиваемый (2015-2020)
Количественные единицы	Доход в млн. долл. США
Охваченные сегменты	Тип продукта (продукты для мониторинга глюкозы, продукты для тестирования на инфекционные заболевания, продукты для кардиометаболического мониторинга, продукты для тестирования на беременность и фертильность, продукты для гематологического тестирования, продукты для мониторинга коагуляции, продукты для тестирования на наркотики, вызывающие зависимость (DOA), продукты для анализа мочи, продукты для тестирования холестерина, продукты для тестирования на маркеры опухолей/рака, продукты для тестирования кала на скрытую кровь и другие), применение (глюкоза в крови, кардиомониторинг, гематологическая коагуляция, анализ цельной крови, мониторинг основных показателей жизнедеятельности, неинвазивный мониторинг Spo2, неинвазивный мониторинг Pco2, переливание крови и другие), режим рецепта (тестирование по рецепту и без рецепта), платформа (анализы бокового потока/иммунохроматографические тесты, тест-полоски, молекулярная диагностика, иммуноанализы, микрофлюидика, клинический биохимический анализ, гематология и другие), Конечный пользователь (клиники, домашняя помощь, больницы, лаборатории, амбулаторные хирургические центры и другие), канал сбыта (прямой тендер, розничные продажи, онлайн-продажи и другие)
Страны, охваченные	Южная Африка, Германия, Франция, Великобритания, Италия, Испания, Нидерланды, Россия, Швейцария, Турция, Бельгия и остальные страны Европы.
Охваченные участники рынка	F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Werfen, Sysmex Europe SE., Danaher, Quidel Corporation, LumiraDx, BD, Abbott, Nova Biomedical, Abaxis, Trividia Health, Inc., Sekisui Diagnostics, Thermo Fisher Scientific Inc., EKF Diagnostics, Trinity Biotech, Chembio Diagnostics, Inc., PTS Diagnostics, binx health, Inc. и QuantuMDx Group Ltd. и другие.

Определение рынка

Рынок тестирования в месте оказания медицинской помощи (POCT) относится к рынку диагностических тестов, которые проводятся в месте нахождения пациента или рядом с ним, предоставляя немедленные результаты для принятия клинических решений. POCT подразумевает проведение медицинских тестов за пределами традиционных лабораторных условий, как правило, в таких местах, как больницы, клиники, амбулаторные центры, врачебные кабинеты и даже дома у пациентов. POCT предназначен для предоставления быстрого и удобного доступа к диагностической информации, что позволяет медицинским работникам принимать немедленные решения о лечении, контролировать состояние пациентов и улучшать общий уход за пациентами. Тесты, проводимые в POCT, охватывают широкий спектр медицинских дисциплин, включая инфекционные заболевания, сердечно-сосудистое здоровье, ведение диабета, беременность и фертильность, онкологию и гематологию.

Динамика рынка тестирования в точках оказания медицинской помощи (POCT)

В этом разделе рассматривается понимание движущих сил рынка, преимуществ, ограничений и проблем. Все это подробно обсуждается ниже:

Драйверы

Рост распространенности инфекционных и хронических заболеваний

Распространенность инфекционных и хронических заболеваний, таких как рак, диабет и сердечно-сосудистые заболевания, стремительно растет по всей Европе. По данным Всемирной организации здравоохранения (ВОЗ), доля хронических заболеваний составила около 60%, что обусловило число смертей. В Европе основной причиной роста числа хронических заболеваний является непрерывный рост численности гериатрического населения. Эти растущие показатели заболеваемости прямо пропорциональны росту POCT, поскольку они используются для диагностики практически всех заболеваний.

Таким образом, резкий рост распространенности хронических заболеваний станет основным драйвером роста рынка, поскольку устройства POCT могут эффективно контролировать заболевание и обеспечивать больший комфорт и возможность мониторинга при необходимости.

Улучшение показателей обращаемости за диагностикой

Повышение квалификации медицинских работников и регулярные обучающие мероприятия для специалистов, проводящих тесты, способствовали улучшению показателей диагностики в регионе, в том числе росту успешной диагностики хронических заболеваний, таких как рак, сердечно-сосудистые заболевания, диабет 2 типа и другие.

Была введена методология, которая включает охват управления, время, затрачиваемое специалистом на диагностику, и оценочные мероприятия для поддержки процесса POCT, что поможет повысить точность информации и поможет принимать более обоснованные решения в плане диагностики. Таким образом, усилия специалистов в области здравоохранения и ИТ, улучшение подготовки специалистов в области здравоохранения, изменение системы оказания медицинской помощи пациентам и улучшение показателей поиска диагноза в регионе ведут к росту рынка.

Спрос на носимые или портативные устройства для контроля уровня глюкозы

Из-за возросшей распространенности диабета среди пациентов в настоящее время глюкометры становятся необходимыми для их выживания, поскольку они помогут определить уровень глюкозы. Благодаря простоте соблюдения POCT обеспечивает комфорт для пациентов, поскольку они могут определить состояние своего здоровья, проверяя его с помощью устройства, что поможет им предотвратить нежелательные проблемы со здоровьем.

Таким образом, запуск новых медицинских устройств для носимых и портативных датчиков уровня глюкозы будет способствовать росту рынка.

Возможности

Стратегические инициативы участников рынка

Рост распространенности хронических и инфекционных заболеваний в Европе требует новых и усовершенствованных наборов и решений POCT с улучшенными показателями эффективности и сокращенным временем цикла из-за роста гериатрического населения, а также для улучшения управления здравоохранением и диагностики для качественной работы. Основные лидеры рынка занимаются полным удовлетворением потребностей медицинских работников и тратят свое время на исследования для производства более качественной продукции, наборов и реагентов.

Например,

В мае 2020 года компания Roche приобрела Stratos Genomics, стартап, находящийся на ранних стадиях развития отрасли технологий секвенирования, с целью дальнейшего развития своего нанопорового секвенатора, который объединяет электронные и биологические компоненты для секвенирования ДНК с целью быстрого, адаптивного и доступного клинического диагностического тестирования.

Таким образом, эти стратегические инициативы участников рынка выступают в качестве возможности, помогающей им стимулировать рост рынка.

Повышение осведомленности и государственное финансирование

Правительство, федерации и основные игроки на рынке участвуют в распространении информации среди общества в развивающихся странах. Эти инициативы игроков и правительства помогают пользователям охватить и воспользоваться политикой, разработанной для стран с низким уровнем дохода и развивающихся стран, и информируют их о болезнях, которые можно предотвратить, если диагностировать их на ранней стадии. Рост POCT в больницах и отделениях неотложной помощи уже активно поощряется правительственными инициативами и распространенностью заболеваний, требующих срочного лечения.

Ограничения/Проблемы

Недостаточная точность продукции POCT

Точность POCT зависит от качества самого теста. Некоторые устройства POCT могут иметь более низкую чувствительность или специфичность по сравнению с лабораторными тестами. Крайне важно использовать высококачественные, проверенные устройства POCT для обеспечения точных результатов. Некоторые медицинские состояния или определенные тесты могут иметь неотъемлемые ограничения с точки зрения точности, независимо от того, проводятся ли они в лаборатории или в месте оказания медицинской помощи. Важно знать об ограничениях и потенциальных источниках ошибок, связанных с определенными устройствами или тестами POCT. В области POCT преаналитические ошибки встречаются довольно часто. В результате эти обстоятельства ограничивают разработку новых продуктов, что препятствует расширению рынка, что приводит к отзыву продукта и осуществляется для постоянного изъятия.

Высокая стоимость продукта POCT

Высокая стоимость продукции POCT, включая устройства для тестирования, картриджи и расходные материалы, может сделать принятие и реализацию программ POCT финансово сложным для поставщиков медицинских услуг, особенно небольших клиник и учреждений. Первоначальные инвестиции, необходимые для приобретения необходимого оборудования и поддержания запаса расходных материалов, могут стать существенным препятствием. Высокая стоимость продукции POCT может косвенно влиять и на пациентов. Если стоимость POCT перекладывается на пациентов, это может сделать тесты недоступными для некоторых лиц, особенно для тех, у кого нет страхового покрытия или высокие франшизы. Это может препятствовать принятию и использованию POCT, поскольку пациенты могут выбирать альтернативные методы тестирования или вообще отказываться от тестирования.

Последние события

В апреле 2022 года компания Sysmex Europe SE представила устройства для тестирования в месте оказания медицинской помощи на 24-м Европейском конгрессе по клинической химии и лабораторной медицине IFCC-EFLM в Мюнхене. Запуск продукта привел к росту партнерства с участниками рынка для использования и распространения устройств POCT, а также к добавлению нового продукта в продуктовый портфель, что привело к росту выручки.
В апреле 2021 года компания Danaher объявила о присоединении известных ученых к новому научному консультативному совету для поддержки разработки новых технологий и привнесения уникальных перспектив в быстро развивающиеся тенденции в области науки и технологий, влияющие на Danaher. Это помогло компании диверсифицировать свой сегментный портфель.

Объем рынка тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе

Рынок тестирования в точках оказания медицинской помощи (POCT) в Южной Африке и Европе сегментирован на шесть заметных сегментов на основе типа продукта, применения, режима рецепта, платформы, конечного пользователя и канала сбыта. Рост среди этих сегментов поможет вам проанализировать сегменты с незначительным ростом в отраслях и предоставить пользователям ценный обзор рынка и рыночные идеи для принятия стратегических решений по определению основных рыночных приложений.

Тип продукта

Продукция для мониторинга уровня глюкозы
Продукция для тестирования на инфекционные заболевания
Продукция для кардиометаболического мониторинга
Продукция для тестирования на беременность и фертильность
Продукция для гематологического тестирования
Продукция для мониторинга коагуляции
Продукция для тестирования на наркотики (DOA)
Продукция для анализа мочи
Продукция для тестирования уровня холестерина
Продукция для тестирования маркеров опухолей/рака
Продукты для скрытого фекального тестирования
Другие

По типу продукции рынок тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе сегментирован на продукты для мониторинга уровня глюкозы, продукты для тестирования на инфекционные заболевания, продукты для кардиометаболического мониторинга, продукты для тестирования на беременность и фертильность, продукты для гематологического тестирования, продукты для мониторинга коагуляции, продукты для тестирования на наркотики, вызывающие зависимость (DOA), продукты для анализа мочи, продукты для тестирования на холестерин, продукты для тестирования на маркеры опухолей/рака, продукты для тестирования кала на скрытую флору и другие.

Приложение

Уровень глюкозы в крови
Мониторинг сердца
Гематология
Коагуляция
Анализ цельной крови
Мониторинг жизненно важных показателей
Неинвазивный мониторинг SpO2
Неинвазивный мониторинг PCO2
Переливание крови
Другие

В зависимости от сферы применения рынок тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе сегментирован на следующие направления: измерение уровня глюкозы в крови, кардиомониторинг, гематология, коагуляция, анализ цельной крови, мониторинг основных показателей жизнедеятельности, неинвазивный мониторинг SpO2, неинвазивный мониторинг PCO2, переливание крови и другие.

Режим рецепта

Тестирование на основе рецепта
Тестирование без рецепта

По принципу выдачи рецептов рынок тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе сегментирован на тестирование по рецепту и тестирование без рецепта.

Платформа

Анализы бокового потока/ Иммунохроматографические тесты
Щупы
Молекулярная диагностика
Иммуноферментный анализ
Микрофлюидика
Анализ клинической химии
Гематология
Другие

На основе платформы рынок тестирования по месту оказания медицинской помощи (POCT) в Южной Африке и Европе сегментирован на иммунохроматографические тесты, тест-полоски, молекулярную диагностику, иммуноанализы, микрофлюидику, клинические химические анализы, гематологию и другие.

Конечный пользователь

Клиники
Уход на дому
Больницы
Лаборатории
Центры амбулаторной хирургии
Другие

По признаку конечного пользователя рынок тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе сегментирован на клиники, учреждения по уходу на дому, больницы, лаборатории, амбулаторные хирургические центры и другие.

Канал распространения

Прямой тендер
Розничные продажи
Онлайн-продажи
Другие

На основе каналов сбыта рынок тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе сегментируется на прямые торги, розничные продажи, онлайн-продажи и другие.

Региональный анализ/информация о рынке тестирования в точках оказания медицинской помощи (POCT)

Проанализирован рынок тестирования по месту оказания медицинской помощи (POCT), а также предоставлены сведения о размерах рынка и тенденциях по странам, типам продуктов, сферам применения, способам назначения, платформам, конечным пользователям и каналам сбыта.

В отчете рассматриваются следующие страны: Южная Африка, Германия, Франция, Великобритания, Италия, Испания, Нидерланды, Россия, Швейцария, Турция, Бельгия и остальные страны Европы.

Ожидается, что Германия будет доминировать благодаря растущей осведомленности и государственному финансированию продукции POCT, что, как ожидается, станет движущей силой регионального рынка в прогнозируемый период.

Спрос на диагностику рака мочевого пузыря будет расти из-за растущих технологических достижений. Различные компании предпринимают инициативы, которые постепенно приводят к росту рынка.

Анализ конкурентной среды и доли рынка тестирования в точках оказания медицинской помощи (POCT)

Конкурентная среда рынка тестирования в точках оказания медицинской помощи (POCT) содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта и доминировании приложений. Приведенные выше данные относятся только к фокусу компаний на рынке.

Некоторые из основных игроков, работающих на рынке, включают F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Werfen, Sysmex Europe SE., Danaher, Quidel Corporation, LumiraDx, BD, Abbott, Nova Biomedical, Abaxis, Trividia Health, Inc., Sekisui Diagnostics, Thermo Fisher Scientific Inc., EKF Diagnostics, Trinity Biotech, Chembio Diagnostics, Inc., PTS Diagnostics, binx health, Inc. и QuantuMDx Group Ltd. и другие.

SKU-70152

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Интерактивная панель анализа данных
Панель анализа компании для возможностей с высоким потенциалом роста
Доступ аналитика-исследователя для настройки и запросов
Анализ конкурентов с помощью интерактивной панели
Последние новости, обновления и анализ тенденций
Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов

Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE

2.8 MARKET END USER COVERAGE GRID

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 STRATEGIC INITIATIVES

5 REGULATORY FRAMEWORK

5.1 REGULATORY SCENARIO IN EUROPE

5.2 REGULATORY SCENARIO IN SOUTH AFRICA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF INFECTIOUS AND CHRONIC DISEASES

6.1.2 IMPROVED DIAGNOSIS-SEEKING RATE

6.1.3 DEMAND FOR WEARABLE OR PORTABLE GLUCOSE MONITORING DEVICES

6.1.4 RISING PREFERENCE FOR HOMECARE TESTING

6.2 RESTRAINTS

6.2.1 LACK OF ACCURACY WITH POCT PRODUCTS

6.2.2 HIGH COST OF POCT PRODUCT

6.2.3 LACK OF TRAINING

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS

6.3.2 RISING AWARENESS AND GOVERNMENT FUNDING

6.4 CHALLENGES

6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

6.4.2 IMPROPER CARE OF POCT DEVICES

7 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 GLUCOSE MONITORING PRODUCTS

7.2.1 STRIPS

7.2.2 METERS

7.2.3 LANCETS AND LANCING DEVICES

7.3 INFECTIOUS DISEASE TESTING PRODUCTS

7.3.1 INFLUENZA TESTING PRODUCTS

7.3.1.1 TRADITIONAL DIAGNOSTIC TEST

7.3.1.1.1 RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)

7.3.1.1.2 DIRECT FLUORESCENT ANTIBODY TEST (DFAT)

7.3.1.1.3 VIRAL CULTURE

7.3.1.1.4 SEROLOGICAL ASSAY

7.3.1.2 MOLECULAR DIAGNOSTIC ASSAY

7.3.1.2.1 RT-PCR

7.3.1.2.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)

7.3.1.2.3 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT)

7.3.1.2.4 SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)

7.3.2 HIV TESTING PRODUCTS

7.3.2.1 TESTING EQUIPMENT

7.3.2.2 TESTING REAGENT

7.3.3 HEPATITIS C TESTING PRODUCTS

7.3.3.1 HCV ANTIBODY TESTS

7.3.3.2 HCV VIRAL LOAD TESTS

7.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING

7.3.4.1 NAAT-BASED SYSTEMS

7.3.4.2 NON–NAAT-BASED SYSTEMS

7.3.5 HEALTHCARE ASSOCIATED INFECTION (HAI) TESTING

7.3.6 RESPIRATORY INFECTION TESTING PRODUCTS

7.3.7 TROPICAL DISEASE TESTING PRODUCTS

7.3.8 COVID 19

7.3.9 OTHER INFECTIOUS DISEASE TESTING PRODUCTS

7.4 CARDIOMETABOLIC MONITORING PRODUCTS

7.4.1 CARDIAC MARKER TESTING PRODUCTS

7.4.1.1 HSTNL

7.4.1.2 BNP

7.4.1.3 D-DIMER

7.4.1.4 CK-MB

7.4.1.5 MYOGLOBIN

7.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS

7.4.2.1 CARTRIDGES

7.4.2.2 REAGENTS

7.4.3 HBA1C TESTING PRODUCTS

7.4.3.1 HBA1C TESTING INSTRUMENTS

7.4.3.2 HBA1C TESTING CONSUMABLES

7.4.4 POC ANALYZER

7.4.5 ECG DEVICES

7.4.5.1 RESTING ECG DEVICES

7.4.5.2 STRESS ECG DEVICES

7.4.5.3 HOLTER MONITORS

7.5 PREGNANCY AND FERTILITY TESTING PRODUCTS

7.5.1 PREGNANCY TESTING PRODUCTS

7.5.1.1 STRIPS/ DIP STICKS AND CARDS

7.5.1.2 MID STREAM DEVICES

7.5.1.3 CASSETTES

7.5.1.4 DIGITAL DEVICES

7.5.1.5 LINE-INDICATOR DEVICES

7.5.2 FERTILITY TESTING PRODUCTS

7.5.2.1 HUMAN CHORIONIC GONADOTROPIN (HCG) URINE TEST

7.5.2.2 FSH URINE TEST

7.5.2.3 LUTEINIZING HORMONE (LH) URINE TEST

7.6 HAEMATOLOGY TESTING PRODUCTS

7.7 COAGULATION MONITORING PRODUCTS

7.7.1 ANTICOAGULATION MONITORING DEVICES

7.7.2 PLATELET FUNCTION MONITORING DEVICES

7.7.3 VISCOELASTIC COAGULATION MONITORING DEVICES

7.8 DRUG-OF-ABUSE (DOA) TESTING PRODUCTS

7.8.1 DOA ANALYZERS

7.8.1.1 IMMUNOASSAYS

7.8.1.2 CHROMATOGRAPHIC DEVICES

7.8.1.3 BREATH ANALYZERS

7.8.2 RAPID TESTING DEVICES

7.8.2.1 URINE TESTING DEVICES

7.8.2.2 ORAL FLUID TESTING DEVICES

7.9 URINALYSIS TESTING PRODUCTS

7.9.1 POC URINE STRIP SELF-TESTING

7.9.2 POC URINE TEST STRIP PROFESSIONAL TESTING

7.1 CHOLESTEROL TESTING PRODUCTS

7.10.1 INSTRUMENTS

7.10.1.1 TABLE-TOP ANALYZERS

7.10.1.2 HAND-HELD ANALYZERS

7.10.2 TESTING KITS

7.11 TUMOR/CANCER MARKER TESTING PRODUCTS

7.12 FECAL OCCULT TESTING PRODUCTS

7.12.1 GUAIAC FOB STOOL TEST

7.12.2 IMMUNO-FOB AGGLUTINATION TEST

7.12.3 LATERAL FLOW IMMUNO-FOB TEST

7.12.4 IMMUNO-FOB ELISA TEST

7.13 OTHERS

8 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 BLOOD GLUCOSE

8.3 CARDIAC MONITORING

8.4 HAEMATOLOGY

8.5 COAGULATION

8.6 WHOLE BLOOD ANALYSIS

8.7 VITAL SIGN MONITORING

8.8 NON- INVASIVE SPO2 MONITORING

8.9 NON- INVASIVE PCO2 MONITORING

8.1 BLOOD TRANSFUSION

8.11 OTHERS

9 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE

9.1 OVERVIEW

9.2 PRESCRIPTION-BASED TESTING

9.3 OVER THE COUNTER TESTING

10 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM

10.1 OVERVIEW

10.2 LATERAL FLOW ASSAYS /IMMUNOCHROMATOGRAPHY TESTS

10.3 DIPSTICKS

10.4 MOLECULAR DIAGNOSTICS

10.5 IMMUNOASSAYS

10.6 MICROFLUIDICS

10.7 CLINICAL CHEMISTRY ASSAY

10.8 HEMATOLOGY

10.9 OTHERS

11 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER

11.1 OVERVIEW

11.2 CLINICS

11.3 HOME CARE

11.4 HOSPITALS

11.5 LABORATORIES

11.6 AMBULATORY SURGERY CENTERS

11.7 OTHERS

12 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

12.4 ONLINE SALES

12.5 OTHERS

13 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET

13.1 EUROPE

13.1.1 GERMANY

13.1.2 U.K.

13.1.3 FRANCE

13.1.4 SPAIN

13.1.5 ITALY

13.1.6 RUSSIA

13.1.7 NETHERLANDS

13.1.8 SWITZERLAND

13.1.9 TURKEY

13.1.10 BELGIUM

13.1.11 REST OF EUROPE

13.2 SOUTH AFRICA

14 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: EUROPE

14.2 COMPANY SHARE ANALYSIS: SOUTH AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 F HOFFMANN-LA ROCHE LTD

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 PRODUCT PORTFOLIO

16.1.4 RECENT DEVELOPMENTS

16.2 SIEMENS HEALTHCARE GMBH

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 PRODUCT PORTFOLIO

16.2.4 RECENT DEVELOPMENTS

16.3 WERFEN

16.3.1 1.3.1 COMPANY SNAPSHOT

16.3.2 PRODUCT PORTFOLIO

16.3.3 RECENT DEVELOPMENT

16.4 SYSMEX EUROPE SE.

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENT

16.5 DANAHER

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENTS

16.6 ABAXIS

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 ABBOTT

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 BD

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENTS

16.9 BINX HEALTH, INC.

16.9.1 COMPANY SNAPSHOT

16.9.2 PRODUCT PORTFOLIO

16.9.3 RECENT DEVELOPMENTS

16.1 CHEMBIO DIAGNOSTICS SYSTEMS, INC

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENTS

16.11 EKF DIAGNOSTICS

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENTS

16.12 LUMIRAXDX

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENTS

16.13 NOVA BIOMEDICAL

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 PTS DIAGNOSTICS

16.14.1 COMPANY SNAPSHOT

16.14.2 PRODUCT PORTFOLIO

16.14.3 RECENT DEVELOPMENTS

16.15 QUANTUMDX GROUP LTD.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 QUIDEL CORPORATION

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENTS

16.17 SEKISUI DIAGNOSTICS

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT

16.18 THERMO FISHER SCIENTIFIC INC.

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENTS

16.19 TRINITY BIOTECH

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENTS

16.2 TRIVIDIA HEALTH, INC.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Список таблиц

TABLE 1 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 SOUTH AFRICA AND EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 3 SOUTH AFRICA AND EUROPE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 SOUTH AFRICA AND EUROPE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 SOUTH AFRICA AND EUROPE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 6 SOUTH AFRICA AND EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 SOUTH AFRICA AND EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 SOUTH AFRICA AND EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 SOUTH AFRICA AND EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 10 SOUTH AFRICA AND EUROPE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 SOUTH AFRICA AND EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 12 SOUTH AFRICA AND EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 13 SOUTH AFRICA AND EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 14 SOUTH AFRICA AND EUROPE ECG DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 15 SOUTH AFRICA AND EUROPE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 16 SOUTH AFRICA AND EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 17 SOUTH AFRICA AND EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 18 SOUTH AFRICA AND EUROPE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 19 SOUTH AFRICA AND EUROPE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 20 SOUTH AFRICA AND EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 21 SOUTH AFRICA AND EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 22 SOUTH AFRICA AND EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 23 SOUTH AFRICA AND EUROPE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 24 SOUTH AFRICA AND EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 25 SOUTH AFRICA AND EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 26 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 27 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 28 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 29 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 30 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 31 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 32 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 33 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 34 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 35 EUROPE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 36 EUROPE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 37 EUROPE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 38 EUROPE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 39 EUROPE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 40 EUROPE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 41 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 42 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 43 EUROPE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 44 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 45 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 46 EUROPE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 47 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 48 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 49 EUROPE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 50 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 51 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 52 EUROPE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 53 EUROPE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 56 EUROPE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 57 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 58 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 59 EUROPE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 60 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 61 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 62 EUROPE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 63 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 64 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 65 EUROPE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 66 EUROPE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 67 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 68 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 69 EUROPE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 70 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 72 EUROPE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 73 EUROPE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 EUROPE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 75 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 77 EUROPE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 78 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 79 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 80 EUROPE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 81 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 82 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 83 EUROPE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 84 EUROPE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 85 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 87 EUROPE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 88 EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 EUROPE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 90 EUROPE FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 91 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 92 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 93 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 94 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 95 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 96 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 97 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 98 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 99 GERMANY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 100 GERMANY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 101 GERMANY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 102 GERMANY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 103 GERMANY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 104 GERMANY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 105 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 106 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 107 GERMANY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 108 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 109 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 110 GERMANY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 111 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 112 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 113 GERMANY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 114 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 115 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 116 GERMANY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 117 GERMANY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 118 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 119 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 120 GERMANY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 121 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 122 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 123 GERMANY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 124 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 125 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 126 GERMANY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 127 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 128 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 129 GERMANY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 130 GERMANY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 131 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 132 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 133 GERMANY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 134 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 135 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 136 GERMANY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 137 GERMANY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 138 GERMANY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 139 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 140 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 141 GERMANY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 142 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 143 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 144 GERMANY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 145 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 146 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 147 GERMANY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 148 GERMANY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 149 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 150 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 151 GERMANY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 152 GERMANY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 153 GERMANY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 154 GERMANY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 155 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 156 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 157 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 158 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 159 GERMANY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 160 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 161 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 162 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 163 U.K. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 164 U.K. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 165 U.K. INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 166 U.K. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 167 U.K. TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 168 U.K. TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 169 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 170 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 171 U.K. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 172 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 173 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 174 U.K. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 175 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 176 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 177 U.K. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 178 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 179 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 180 U.K. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 181 U.K. CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 182 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 183 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 184 U.K. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 185 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 186 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 187 U.K. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 188 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 189 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 190 U.K. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 191 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 192 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 193 U.K. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 194 U.K. PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 195 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 196 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 197 U.K. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 198 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 199 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 200 U.K. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 201 U.K. COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 202 U.K. DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 203 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 204 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 205 U.K. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 206 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 207 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 208 U.K. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 209 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 210 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 211 U.K. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 212 U.K. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 213 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 214 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 215 U.K. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 216 U.K. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 217 U.K. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 218 U.K. FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 219 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 220 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 221 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 222 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 223 U.K. POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 224 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 225 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 226 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 227 FRANCE GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 228 FRANCE INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 229 FRANCE INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 230 FRANCE TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 231 FRANCE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 232 FRANCE TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 233 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 234 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 235 FRANCE MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 236 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 237 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 238 FRANCE HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 239 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 240 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 241 FRANCE HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 242 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 243 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 244 FRANCE SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 245 FRANCE CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 246 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 247 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 248 FRANCE CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 249 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 250 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 251 FRANCE BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 252 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 253 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 254 FRANCE HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 255 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 256 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 257 FRANCE ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 258 FRANCE PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 259 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 260 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 261 FRANCE PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 262 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 263 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 264 FRANCE FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 265 FRANCE COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 266 FRANCE DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 267 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 268 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 269 FRANCE DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 270 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 271 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 272 FRANCE RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 273 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 274 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 275 FRANCE URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 276 FRANCE CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 277 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 278 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 279 FRANCE INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 280 FRANCE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 281 FRANCE FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 282 FRANCE FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 283 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 284 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 285 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 286 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 287 FRANCE POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 288 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 289 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 290 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 291 SPAIN GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 292 SPAIN INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 293 SPAIN INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 294 SPAIN TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 295 SPAIN TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 296 SPAIN TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 297 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 298 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 299 SPAIN MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 300 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 301 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 302 SPAIN HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 303 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 304 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 305 SPAIN HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 306 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 307 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 308 SPAIN SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 309 SPAIN CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 310 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 311 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 312 SPAIN CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 313 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 314 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 315 SPAIN BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 316 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 317 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 318 SPAIN HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 319 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 320 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 321 SPAIN ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 322 SPAIN PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 323 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 324 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 325 SPAIN PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 326 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 327 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 328 SPAIN FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 329 SPAIN COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 330 SPAIN DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 331 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 332 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 333 SPAIN DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 334 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 335 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 336 SPAIN RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 337 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 338 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 339 SPAIN URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 340 SPAIN CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 341 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 342 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 343 SPAIN INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 344 SPAIN FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 345 SPAIN FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 346 SPAIN FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 347 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 348 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 349 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 350 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 351 SPAIN POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 352 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 353 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 354 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 355 ITALY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 356 ITALY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 357 ITALY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 358 ITALY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 359 ITALY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 360 ITALY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 361 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 362 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 363 ITALY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 364 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 365 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 366 ITALY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 367 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 368 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 369 ITALY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 370 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 371 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 372 ITALY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 373 ITALY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 374 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 375 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 376 ITALY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 377 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 378 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 379 ITALY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 380 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 381 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 382 ITALY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 383 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 384 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 385 ITALY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 386 ITALY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 387 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 388 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 389 ITALY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 390 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 391 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 392 ITALY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 393 ITALY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 394 ITALY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 395 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 396 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 397 ITALY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 398 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 399 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 400 ITALY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 401 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 402 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 403 ITALY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 404 ITALY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 405 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 406 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 407 ITALY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 408 ITALY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 409 ITALY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 410 ITALY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 411 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 412 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 413 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 414 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 415 ITALY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 416 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 417 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 418 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 419 RUSSIA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 420 RUSSIA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 421 RUSSIA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 422 RUSSIA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 423 RUSSIA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 424 RUSSIA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 425 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 426 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 427 RUSSIA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 428 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 429 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 430 RUSSIA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 431 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 432 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 433 RUSSIA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 434 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 435 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 436 RUSSIA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 437 RUSSIA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 438 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 439 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 440 RUSSIA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 441 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 442 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 443 RUSSIA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 444 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 445 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 446 RUSSIA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 447 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 448 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 449 RUSSIA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 450 RUSSIA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 451 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 452 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 453 RUSSIA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 454 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 455 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 456 RUSSIA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 457 RUSSIA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 458 RUSSIA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 459 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 460 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 461 RUSSIA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 462 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 463 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 464 RUSSIA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 465 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 466 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 467 RUSSIA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 468 RUSSIA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 469 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 470 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 471 RUSSIA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 472 RUSSIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 473 RUSSIA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 474 RUSSIA FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 475 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 476 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 477 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 478 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 479 RUSSIA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 480 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 481 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 482 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 483 NETHERLANDS GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 484 NETHERLANDS INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 485 NETHERLANDS INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 486 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 487 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 488 NETHERLANDS TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 489 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 490 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 491 NETHERLANDS MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 492 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 493 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 494 NETHERLANDS HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 495 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 496 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 497 NETHERLANDS HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 498 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 499 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 500 NETHERLANDS SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 501 NETHERLANDS CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 502 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 503 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 504 NETHERLANDS CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 505 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 506 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 507 NETHERLANDS BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 508 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 509 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 510 NETHERLANDS HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 511 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 512 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 513 NETHERLANDS ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 514 NETHERLANDS PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 515 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 516 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 517 NETHERLANDS PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 518 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 519 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 520 NETHERLANDS FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 521 NETHERLANDS COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 522 NETHERLANDS DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 523 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 524 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 525 NETHERLANDS DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 526 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 527 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 528 NETHERLANDS RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 529 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 530 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 531 NETHERLANDS URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 532 NETHERLANDS CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 533 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 534 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 535 NETHERLANDS INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 536 NETHERLANDS FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 537 NETHERLANDS FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 538 NETHERLANDS FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 539 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 540 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 541 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 542 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 543 NETHERLANDS POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 544 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 545 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 546 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 547 SWITZERLAND GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 548 SWITZERLAND INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 549 SWITZERLAND INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 550 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 551 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 552 SWITZERLAND TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 553 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 554 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 555 SWITZERLAND MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 556 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 557 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 558 SWITZERLAND HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 559 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 560 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 561 SWITZERLAND HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 562 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 563 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 564 SWITZERLAND SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 565 SWITZERLAND CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 566 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 567 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 568 SWITZERLAND CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 569 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 570 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 571 SWITZERLAND BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 572 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 573 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 574 SWITZERLAND HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 575 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 576 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 577 SWITZERLAND ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 578 SWITZERLAND PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 579 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 580 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 581 SWITZERLAND PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 582 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 583 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 584 SWITZERLAND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 585 SWITZERLAND COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 586 SWITZERLAND DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 587 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 588 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 589 SWITZERLAND DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 590 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 591 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 592 SWITZERLAND RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 593 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 594 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 595 SWITZERLAND URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 596 SWITZERLAND CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 597 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 598 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 599 SWITZERLAND INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 600 SWITZERLAND FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 601 SWITZERLAND FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 602 SWITZERLAND FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 603 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 604 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 605 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 606 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 607 SWITZERLAND POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 608 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 609 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 610 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 611 TURKEY GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 612 TURKEY INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 613 TURKEY INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 614 TURKEY TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 615 TURKEY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 616 TURKEY TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 617 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 618 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 619 TURKEY MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 620 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 621 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 622 TURKEY HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 623 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 624 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 625 TURKEY HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 626 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 627 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 628 TURKEY SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 629 TURKEY CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 630 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 631 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 632 TURKEY CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 633 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 634 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 635 TURKEY BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 636 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 637 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 638 TURKEY HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 639 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 640 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 641 TURKEY ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 642 TURKEY PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 643 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 644 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 645 TURKEY PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 646 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 647 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 648 TURKEY FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 649 TURKEY COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 650 TURKEY DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 651 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 652 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 653 TURKEY DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 654 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 655 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 656 TURKEY RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 657 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 658 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 659 TURKEY URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 660 TURKEY CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 661 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 662 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 663 TURKEY INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 664 TURKEY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 665 TURKEY FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 666 TURKEY FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 667 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 668 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 669 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 670 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 671 TURKEY POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 672 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 673 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 674 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 675 BELGIUM GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 676 BELGIUM INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 677 BELGIUM INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 678 BELGIUM TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 679 BELGIUM TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 680 BELGIUM TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 681 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 682 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 683 BELGIUM MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 684 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 685 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 686 BELGIUM HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 687 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 688 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 689 BELGIUM HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 690 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 691 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 692 BELGIUM SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 693 BELGIUM CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 694 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 695 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 696 BELGIUM CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 697 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 698 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 699 BELGIUM BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 700 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 701 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 702 BELGIUM HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 703 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 704 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 705 BELGIUM ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 706 BELGIUM PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 707 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 708 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 709 BELGIUM PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 710 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 711 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 712 BELGIUM FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 713 BELGIUM COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 714 BELGIUM DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 715 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 716 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 717 BELGIUM DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 718 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 719 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 720 BELGIUM RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 721 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 722 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 723 BELGIUM URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 724 BELGIUM CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 725 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 726 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 727 BELGIUM INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 728 BELGIUM FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 729 BELGIUM FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 730 BELGIUM FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 731 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 732 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 733 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 734 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 735 BELGIUM POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 736 REST OF EUROPE POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 737 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 738 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 739 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 740 SOUTH AFRICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 741 SOUTH AFRICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 742 SOUTH AFRICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 743 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 744 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 745 SOUTH AFRICA TRADITIONAL DIAGNOSTIC TEST (RIDT) IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 746 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 747 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 748 SOUTH AFRICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 749 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 750 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 751 SOUTH AFRICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 752 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 753 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 754 SOUTH AFRICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 755 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 756 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 757 SOUTH AFRICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 758 SOUTH AFRICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 759 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 760 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 761 SOUTH AFRICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 762 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 763 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 764 SOUTH AFRICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 765 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 766 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 767 SOUTH AFRICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 768 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 769 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 770 SOUTH AFRICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 771 SOUTH AFRICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 772 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 773 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 774 SOUTH AFRICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 775 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 776 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 777 SOUTH AFRICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 778 SOUTH AFRICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 779 SOUTH AFRICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 780 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 781 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 782 SOUTH AFRICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 783 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 784 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 785 SOUTH AFRICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 786 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 787 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 788 SOUTH AFRICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 789 SOUTH AFRICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 790 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 791 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 792 SOUTH AFRICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 793 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 794 SOUTH AFRICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (UNITS)

TABLE 795 SOUTH AFRICA FECAL OCCULT PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2021-2030 (ASP)

TABLE 796 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2021-2030 (USD MILLION)

TABLE 797 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2021-2030 (USD MILLION)

TABLE 798 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2021-2030 (USD MILLION)

TABLE 799 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 800 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Список рисунков

FIGURE 1 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION

FIGURE 2 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DATA TRIANGULATION

FIGURE 3 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DROC ANALYSIS

FIGURE 4 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: MARKET END USER COVERAGE GRID

FIGURE 8 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION

FIGURE 11 RISING PREVALENCE OF CHRONIC DISEASES AND RISING PATIENT INCLINATION TOWARDS POINT-OF-CARE TESTING ARE EXPECTED TO DRIVE THE GROWTH OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET FROM 2023 TO 2030

FIGURE 12 THE GLUCOSE MONITORING PRODUCTS SEGMENT, IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET

FIGURE 14 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, 2022

FIGURE 19 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, 2023-2030 (USD MILLION)

FIGURE 20 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, CAGR (2023-2030)

FIGURE 21 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 22 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2022

FIGURE 23 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2023-2030 (USD MILLION)

FIGURE 24 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, CAGR (2023-2030)

FIGURE 25 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE

FIGURE 26 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, 2022

FIGURE 27 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, 2023-2030 (USD MILLION)

FIGURE 28 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, CAGR (2023-2030)

FIGURE 29 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PLATFORM, LIFELINE CURVE

FIGURE 30 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, 2022

FIGURE 31 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 32 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 36 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 SOUTH AFRICA AND EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: SNAPSHOT (2022)

FIGURE 39 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2022)

FIGURE 40 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2023 & 2030)

FIGURE 41 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE (2023-2030)

FIGURE 43 EUROPE POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY SHARE 2022 (%)

FIGURE 44 SOUTH AFRICA POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY SHARE 2022 (%)

View Detailed Information

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

How Big is the South Africa and Europe point-of-care-testing POCT market ?

South Africa and Europe point-of-care-testing POCT market grows with a CAGR of 9.3% and will reach USD 17,289.45 million by 2030 from USD 8,565.13 million in 2022.

Which market segments are covered in the South Africa and Europe point-of-care-testing POCT market report?

South Africa and Europe point-of-care-testing (POCT) market is segmented into six notable segments based on product type, application, prescription mode, platform, end user, and distribution channel.

Who are the major players operating in the South Africa and Europe point-of-care-testing POCT market?

Some of the major players operating in the market are F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, Werfen, Sysmex Europe SE., Danaher, Quidel Corporation, LumiraDx, BD, Abbott, Nova Biomedical, Abaxis, Trividia Health, Inc., Sekisui Diagnostics, Thermo Fisher Scientific Inc., EKF Diagnostics, Trinity Biotech, Chembio Diagnostics, Inc., PTS Diagnostics, binx health, inc., and QuantuMDx Group Ltd. among others.

Which countries data are covered in the South Africa and Europe point-of-care-testing POCT market report?

The countries covered in this report are South Africa, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, and the rest of Europe.

Which region will dominate the South Africa and Europe point-of-care-testing POCT market?

Germany is expected to dominate due to rising awareness and government funding for POCT products which is expected to drive the regional market in the forecasted period.

Рынок тестирования в пунктах оказания медицинской помощи (POCT) в Южной Африке и Европе – тенденции отрасли и прогноз до 2030 года

Рынок тестирования в пунктах оказания медицинской помощи (POCT) в Южной Африке и Европе – тенденции отрасли и прогноз до 2030 года

South Africa And Europe Poct Market

CAGR : 9.30 %

Анализ и идеи рынка тестирования в пунктах оказания медицинской помощи (POCT) в Южной Африке и Европе

Динамика рынка тестирования в точках оказания медицинской помощи (POCT)

Объем рынка тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе

Региональный анализ/информация о рынке тестирования в точках оказания медицинской помощи (POCT)

Анализ конкурентной среды и доли рынка тестирования в точках оказания медицинской помощи (POCT)

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Отчеты

Обзор рынка

Поддерживать

Решения

Рынок тестирования в пунктах оказания медицинской помощи (POCT) в Южной Африке и Европе – тенденции отрасли и прогноз до 2030 года

Рынок тестирования в пунктах оказания медицинской помощи (POCT) в Южной Африке и Европе – тенденции отрасли и прогноз до 2030 года

South Africa And Europe Poct Market

CAGR : 9.30 %

Анализ и идеи рынка тестирования в пунктах оказания медицинской помощи (POCT) в Южной Африке и Европе

Динамика рынка тестирования в точках оказания медицинской помощи (POCT)

Объем рынка тестирования в местах оказания медицинской помощи (POCT) в Южной Африке и Европе

Региональный анализ/информация о рынке тестирования в точках оказания медицинской помощи (POCT)

Анализ конкурентной среды и доли рынка тестирования в точках оказания медицинской помощи (POCT)

Get online access to the report on the World's First Market Intelligence Cloud

Содержание

Список таблиц

Список рисунков

Методология исследования

Доступна настройка

Часто задаваемые вопросы

Просмотр связанных страниц